{"doi":"10.1016/j.coph.2013.04.003","title":"Targeted cancer immunotherapy","abstract":null,"journal":"Current Opinion in Pharmacology","year":2013,"id":604510,"datarank":1.3736459227355895,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"self_citation_contribution":0.5495342469194471,"citation_network_contribution":0.8241116758161423,"self_endowment_contribution":0.5495342469194471,"citer_contribution":0.8241116758161423,"corpus_percentile":null,"corpus_rank":null,"citation_count":38,"citer_count":37,"citers_with_citation_signal":28,"citers_with_endowment":28,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1551043,"name":"Alexei Shir","orcid":null,"position":1,"is_corresponding":false},{"id":149686,"name":"Alexander Levitzki","orcid":null,"position":2,"is_corresponding":false},{"id":1183008,"name":"Maya Zigler","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Targeted cancer immunotherapy","abstract":"The understanding that the immune system plays a dual role in cancer progression has led to the recent development of targeted immunotherapies. These treatments, which aim to harness the immune system against cancer, include monoclonal antibodies, immune adjuvants, cell-based therapy and vaccines. Although numerous immune-targeted treatment modalities have entered the clinic, most have shown limited efficacy. The intrinsic heterogeneity and genomic instability of the tumor, coupled with immune suppression induced by both the tumor and its microenvironment, remain the main obstacles to the success of these therapies. We believe that the primary objective of the new generation of therapies must be to reinstate immune surveillance against primary and metastatic tumor cells, while inhibiting the immune suppressive microenvironment. Most probably this will be achieved by combining several treatment modalities. This paper will briefly review current immunotherapies and their promise, as well as the obstacles associated with them.","is_dataset_classified":null,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23648271","pmcid":null,"openalex_id":"https://openalex.org/W2074869009","authors":[],"funders":[{"funder_name":"European Research Council","grant_id":"600950","title":null},{"funder_name":"European Commission","grant_id":"249898","title":"Eradication of tumors by targeting dsRNA selectively to cancer cells and recruitment of the innate immune system"}],"total_grants":2,"fwci":2.9653,"citation_percentile":0.91589385,"influential_citations":0,"citation_trend":[{"year":2013,"count":3},{"year":2014,"count":9},{"year":2015,"count":5},{"year":2016,"count":5},{"year":2017,"count":2},{"year":2019,"count":2},{"year":2020,"count":2},{"year":2021,"count":1},{"year":2022,"count":2},{"year":2023,"count":2},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"closed","license":"Elsevier TDM","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1471489213000520?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1471489213000520?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.coph.2013.04.003","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23648271","host_type":"repository"},{"url":"https://dx.doi.org/10.1016/j.coph.2013.04.003","host_type":""},{"url":"http://dx.doi.org/10.1016/j.coph.2013.04.003","host_type":""}],"fields_of_study":["Immunotherapy and Immune Responses","Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research","0301 basic medicine","0303 health sciences","03 medical and health sciences","Animals","Antibodies","Antigens, Neoplasm","Antineoplastic Agents","Cancer Vaccines","Humans","Immunotherapy","Neoplasms"],"mesh_terms":["Animals","Antibodies","Antigens, Neoplasm","Antineoplastic Agents","Humans","Immunotherapy","Neoplasms","Cancer Vaccines"],"keywords":["Immune system","Immunotherapy","Tumor microenvironment","Medicine","Monoclonal antibody","Cancer","Cancer immunotherapy","Immunology","Modalities","Cancer research","Antibody","Internal medicine","Antigens, Neoplasm","Neoplasms","Animals","Humans","Antineoplastic Agents","Cancer Vaccines","Antibodies"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T00:18:07.715317Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}